Primary vitreoretinal lymphoma

Dimitrios Kalogeropoulos(Birmingham and Midland Eye Centre), George Vartholomatos(University Hospital of Ioannina), Arijit Mitra(Birmingham and Midland Eye Centre), Ibrahim Elaraoud(Birmingham and Midland Eye Centre), Soon Wai Ch’ng(Birmingham and Midland Eye Centre), Anastasia Zikou(University of Ioannina), Alexandra Papoudou‐Bai(University of Ioannina), Marilita M. Moschos(National and Kapodistrian University of Athens), Panagiotis Kanavaros(University of Ioannina), Chris Kalogeropoulos(University of Ioannina)
Saudi Journal of Ophthalmology
January 1, 2019
Cited by 47Open Access
Full Text

Abstract

Primary vitreoretinal lymphoma (PVRL) is a rare ocular lymphoid malignancy, which consists a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma. The involvement of eyes is estimated to be approximately 20% of PCNSL, but the brain involvement may be up to 80% of PVRL. Typically, PVRL is a high grade B-cell malignancy of the retina and needs to be assorted from choroidal low-grade B-cell lymphomas. Very often PVRL masquerades and can be erroneously diagnosed as chronic uveitis, white dot syndromes or other neoplasms. Establishing an accurate diagnosis may involve cytology/pathology, immunohistochemistry, flow cytometry, molecular pathology and cytokine profile analysis. There is inadequate information about PVRL's true incidence, ethnic/geographical variation and pathogenetic mechanisms. The therapeutic approach of PVRL involves aggressive chemotherapy and radiation therapy. Although PVRL tends to have a good response to the initial treatment, the prognosis is poor and the survival restricted due to the high relapse rates and CNS involvement.


Related Papers

No related papers found

Powered by citation graph analysis